Clinical Trial

Study of EVO756 in Adults With Migraine

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Protocol Amendment History 3 changes
notable Trial sites expanded: 14 -> 20 locations 2026-08-11
critical Recruitment opened 2026-07-02
notable Trial sites expanded: 0 -> 14 locations 2026-07-02
Trial Details
NCT Number NCT07616128
Lead Sponsor Evommune, Inc.
Conditions Migraine
Enrollment 330 participants
Start Date 2026-07-29
Primary Completion 2027-10 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-10